Log in to save to my catalogue

Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is T...

Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is T...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmed_primary_28152531

Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE)

About this item

Full title

Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE)

Publisher

Basel, Switzerland: S. Karger AG

Journal title

Neuroendocrinology, 2018-01, Vol.106 (1), p.38-46

Language

English

Formats

Publication information

Publisher

Basel, Switzerland: S. Karger AG

More information

Scope and Contents

Contents

Background: The best chemotherapy regimen for well- differentiated pancreatic neuroendocrine tumours (pNETs) with a Ki-67 index ≥10% is still debated. We evaluated the antitumour efficacy of various first-line chemotherapy regimens (streptozocin based, platinum based, or dacarbazine/temozolomide based) in this situation. Methods: In this retrospect...

Alternative Titles

Full title

Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE)

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmed_primary_28152531

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmed_primary_28152531

Other Identifiers

ISSN

0028-3835

E-ISSN

1423-0194

DOI

10.1159/000457955

How to access this item